Developing the next generation microspheres for targeted interventional treatment of liver malignancies.

Learn more

Unique

The first and only commercial radioembolization solution based on holmium-166.

Imageable

Quantitative SPECT and MR imaging properties enable dosimetric treatment verication

Proven

Based on more than 20 years of physician-led technological advancement and clinical research

Quirem Medical

Quirem Medical is an emerging medical device company with a mission to develop the next generation microspheres for targeted interventional treatment of liver malignancies. Our core product, QuiremSpheres®, consists of holmium microspheres that have the unique ability to be accurately and quantitatively imaged.

Every year, close to 700,000 people die from primary liver cancer and a similar number of patients die from secondary, metastatic malignancies in the liver. Unfortunately, treatment options are still limited and as a consequence the mortality-over-incidence ratio is very high: 0.93. The treatment of cancer in the liver with radioembolization has shown substantial efficacy, even though the current treatment with Yttrium-90 is performed in a veritable “black-box”. Treatment efficacy and success can therefore be significantly improved by enabling effective dosimetry and MRI-based imaging to assist the physician prior, during and after the procedure. Compared to the current radioembolization products using Yttrium-90, the application of Holmium-166 based QuiremSpheres® in the treatment of liver-cancer brings several important benefits.